Prelude Therapeutics. has filed a patent for bifunctional compounds with a target protein binding and E3 ubiquitin ligase binding moiety. The compound of Formula (I) is disclosed for pharmaceutical use. GlobalData’s report on Prelude Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Prelude Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Prelude Therapeutics's grant share as of January 2024 was 14%. Grant share is based on the ratio of number of grants to total number of patents.
The patent application (Publication Number: US20240018158A1) discloses a compound of Formula (I) represented as PTM-ULM (I) or its pharmaceutically acceptable salt or solvate. The compound includes a moiety of Formula IA, with various chemical moieties represented by A, q, R1a, R1b, R1c, R1d, and R1e. The claims further detail the specific structures and substitutions permissible for R1, including the presence of cycloalkyl, heterocyclyl, aryl, and heteroaryl groups. Additionally, the claims outline different variations of the compound based on the values of q, R1, and other substituents, providing a comprehensive framework for the chemical composition of the compound.
Moreover, the claims delve into the specific configurations and substitutions allowed for different parts of the compound, such as Formula IA-1, IA-2, IA-3, and IA-4, each with distinct structural characteristics. The claims also specify the permissible values for variables like m, n, s, and z, further defining the compound's composition. Additionally, the claims detail the possible substitutions for R3, R9, R10, R7, R8, and R11, providing a comprehensive guide to the chemical makeup of the compound. Overall, the patent application presents a detailed and structured description of the compound's formula, variations, and permissible substitutions, offering valuable insights for potential pharmaceutical applications.
To know more about GlobalData’s detailed insights on Prelude Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
